

Press Release

08 October 2021 15:20:00 CEST

2cureX provides a Live Strategy Update on the company's product portfolio and commercialization strategy on the 12th of October 2021.

2cureX AB (publ), an IVD diagnostic company that is pioneering the use of 3D microtumors (tumoroids) to guide the drug treatment of solid cancers, will hold a Live Strategy Update session on 12th October at 13:00 (CET). Presentations will be followed by a Questions & Answers discussion moderated by Redeye's Equity Analyst, Erik Nordström.

2cureX's CEO Fernando Andreu, together with Ole Thastrup (CSO), Pia van der Zee (VP of Marketing) and Jesper Floyd Kristiansen (VP of Sales) will present how the unique IndiTreat® platform is addressing a burning issue in oncology, and which strategy and commercialization activities are being conducted to introduce the first IndiTreat® product into the European market.

Link to Strategy Update webcast:

<https://www.redeye.se/events/818830/strategy-update-2curex>

Link to registration:

https://www.lyyti.fi/reg/Strategy_Update_2cureX

The presentation will be held in English.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first IndiTreat® test is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer facing their third line of therapy. Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related *In Vitro Diagnostic* (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

Attachments

[2cureX provides a Live Strategy Update on the company's product portfolio and commercialization strategy on the 12th of October 2021.](#)